RSV in Older Adults: What Recent CDC and FDA Updates Mean for Seniors in 2026

By Brian Bateman | Public Health and Medical Writer

The bottom line

Respiratory syncytial virus (RSV) can cause serious illness in adults 60 and older. In the past year, federal health officials have updated guidance on RSV vaccines for older adults. If you or a loved one is over 60—especially with heart, lung, or immune conditions—this is a good time to review your protection plan with a clinician.

RSV is best known for affecting infants, but the CDC reports that each year in the United States, RSV leads to tens of thousands of hospitalizations among adults age 65 and older. Many cases occur in the fall and winter, alongside flu and COVID-19.

What is RSV, and why does it matter for seniors?

RSV is a common respiratory virus that spreads through droplets when people cough, sneeze, or talk. It can also spread by touching contaminated surfaces and then touching your face.

In healthy younger adults, RSV often feels like a bad cold. In older adults, especially those with:

Chronic heart disease
Chronic lung disease (such as COPD or asthma)
Diabetes
Weakened immune systems
Advanced age (75 and older)

the infection can lead to pneumonia, worsening of underlying conditions, hospitalization, and in some cases, death.

What changed recently?

In 2023 and 2024, the U.S. Food and Drug Administration (FDA) approved the first RSV vaccines for older adults. The CDC later recommended RSV vaccination for adults 60 and older using shared clinical decision-making—meaning patients and clinicians decide together based on individual risk.

More recently, the CDC updated its guidance to clarify which older adults are most likely to benefit, particularly:

Adults 75 and older
Adults 60–74 with chronic medical conditions
Residents of long-term care facilities

These recommendations are based on clinical trials reviewed by the FDA showing that the vaccines reduced the risk of lower respiratory tract disease caused by RSV in adults 60 and older. The original studies were randomized controlled trials—considered a strong form of evidence—but followed participants for limited periods, so researchers continue to monitor long-term effectiveness and safety.

How effective are the RSV vaccines?

In clinical trials published in major medical journals and reviewed by the FDA, RSV vaccines reduced the risk of symptomatic lower respiratory tract disease by a significant margin during the first RSV season after vaccination. Protection appeared strongest against more severe illness.

However, there are important limitations:

Most trials followed participants for one or two RSV seasons.
Real-world effectiveness data are still being collected.
As with flu vaccines, protection may decrease over time.

Ongoing monitoring by the CDC and FDA helps identify rare side effects and better understand how long protection lasts.

What about side effects?

According to FDA and CDC safety data, most side effects have been mild to moderate and temporary. These may include:

Soreness at the injection site
Fatigue
Headache
Muscle pain

After initial rollout, federal health officials investigated rare reports of certain neurologic conditions, such as Guillain-Barré syndrome. So far, monitoring systems such as the FDA’s MedWatch and CDC’s safety surveillance programs continue to assess whether any increased risk exists. At this time, public health agencies state that for many high-risk older adults, the benefits of vaccination outweigh potential risks—but decisions should be individualized.

How RSV spreads in communities and care facilities

For older adults, especially those in nursing homes or assisted living, RSV can spread quickly during respiratory virus season. Crowded indoor settings, shared dining areas, and close contact with caregivers increase transmission risk.

Caregivers and family members play an important role in prevention. Basic steps still matter:

Stay home when sick.
Wash hands regularly.
Improve indoor ventilation when possible.
Keep up with recommended vaccines (RSV, flu, COVID-19).

When to seek medical care

Older adults should contact a healthcare provider if they experience:

Shortness of breath
Chest pain or pressure
Worsening cough
High fever
Confusion or unusual fatigue

RSV symptoms can overlap with flu and COVID-19, so testing may be needed to guide treatment decisions.

Cost and insurance coverage

Under current federal policy, Medicare Part D covers recommended adult vaccines, including RSV vaccines, with no out-of-pocket cost for beneficiaries. Private insurance plans generally cover CDC-recommended vaccines, though coverage details can vary. Seniors should confirm coverage with their plan or pharmacist.

What remains uncertain?

Researchers are still studying:

How long protection lasts
Whether boosters will be needed
How well vaccines perform in very frail adults
Long-term rare side effect risks

This is typical for newly introduced vaccines. Public health guidance may evolve as more real-world data become available.

What this means for older adults and families

If you are 75 or older—or 60 and older with chronic health conditions—RSV vaccination is worth discussing with your healthcare provider before the next respiratory virus season.

RSV is common, but for seniors, it is not always mild. Prevention steps, early care for symptoms, and staying up to date on recommended vaccines can reduce the risk of severe illness.

For caregivers and family members, protecting older loved ones includes staying home when ill, encouraging vaccination where appropriate, and recognizing early warning signs of respiratory distress.

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.

Sources

Centers for Disease Control and Prevention (CDC) – RSV in Older Adults
U.S. Food and Drug Administration (FDA) – RSV Vaccine Approvals and Safety Communications
CDC Advisory Committee on Immunization Practices (ACIP) recommendations
Medicare.gov – Vaccine Coverage Information